Senlis

This research aims to understand how neonatologists decide when extremely preterm infants, born before 28 weeks of gestational age, are ready to be taken off mechanical ventilation during the first two weeks of life. It focuses on the link between clinical assessments of extubation readiness and actual success, defined as no need for reintubation within seven days. The study also seeks to identify factors influencing these decisions and outcomes using both qualitative and quantitative data from several NICUs in France. The study involves no interventions or treatments but collects prospective information from attending physicians through questionnaires completed daily for the first 15 days of life while the infants are mechanically ventilated. Researchers will record reasons for extubation or non-extubation and monitor respiratory outcomes, including extubation failure rates and the duration of various types of respiratory support up to four months of age. Mortality and complications related to intubation will also be documented. Participants will be closely observed throughout their NICU stay, with data collected on respiratory status, mechanical ventilation duration, and clinical decisions regarding extubation. The primary outcome is the reasons for not extubating during the first 15 days of life, assessed multiple times daily early on and daily thereafter. Secondary outcomes include extubation readiness perceptions, extubation failure, bronchopulmonary dysplasia occurrence, length of NICU stay, and mortality up to five months of age. The study will conclude when patients are discharged or definitively weaned off respiratory support.

Researchers are investigating the best first-line treatment strategy for women with advanced epithelial ovarian cancer. This randomized phase II study compares two therapeutic approaches following initial surgery, based on the completeness of tumor removal. The study is conducted across multiple centers to evaluate which strategy may lead to better outcomes for patients with this condition. Participants receive either a combination of carboplatin and paclitaxel chemotherapy given intravenously with surgery, or a combination of cisplatin and epirubicin chemotherapy with surgery. Cisplatin is administered intraperitoneally if no visible tumor remains after surgery, otherwise intravenously. The treatment includes six cycles of chemotherapy every three weeks, and in some cases, a second surgery during treatment if there is remaining disease and an operable response. Throughout the study, participants will be monitored for pathological complete peritoneal response over two years, quality of life assessments at multiple points, and treatment-related side effects. Long-term outcomes such as event-free survival and overall survival will be evaluated at five and ten years. The study involves regular assessments including surgical responses and patient-reported outcomes, with careful safety monitoring during and after treatment.